This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This opening paragraph covers which world indices qualify as total return indices and how dividends boost overall performance.
21,269 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Ripple unveils a day-one Open USD partnership as XRP hovers near $1, with RLUSD clearing regulatory hurdles and insti...
A two-day injunction hearing opens in federal court in Chicago as Zillow fights to keep access to the Chicagoland MLS...
Lizex.io announces a global B2B partnership program, linking crypto wallets, rate aggregators, and fintech apps to it...
A New York Supreme Court filing brings a human claimant into a case over billions in dormant Bitcoin. The move could ...
A widower inherits a Roth IRA worth $250,000 and learns the earnings may be taxed if withdrawn before the five-year c...
Two sector income ETFs are delivering yields well above the S&P 500 as investors price in a possible recession. The g...
Retirees are eyeing Spain's Costa del Sol for a modest, manageable life on a $35,000 annual budget. This report break...
AMD and Palantir posted contrasting Q1 2026 results, underscoring hardware-led AI growth versus enterprise software a...
Three blue-chip names have slipped on the chart while trading below intrinsic value, offering income and upside for p...
Tenable’s stock jumped on Monday, marking a sharp continuation of a rally that started in the spring. This article di...
Nu Holdings faced a 20% stock drop in the first half of the year. This piece breaks down the mix of competition, macr...